Emerging studies have also found that CXCL13 can be served as a potential biomarker for other autoimmune diseases and autoimmune-related disorders such as type 1 diabetes mellitus (T1DM), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), Graves’ disease (GD), bullous pemphigoid (BP), psoriasis, systemic sclerosis (SSc), autoimmune pancreatitis (AIP), and common variable immunodeficiency (CVID). This evidence concerns the gene CXCL13 and autoimmune pancreatitis.